CN1760370A - Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase - Google Patents
Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase Download PDFInfo
- Publication number
- CN1760370A CN1760370A CN 200410064908 CN200410064908A CN1760370A CN 1760370 A CN1760370 A CN 1760370A CN 200410064908 CN200410064908 CN 200410064908 CN 200410064908 A CN200410064908 A CN 200410064908A CN 1760370 A CN1760370 A CN 1760370A
- Authority
- CN
- China
- Prior art keywords
- phosphonuclease
- nucleotidase
- reagent
- activity
- damping fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 27
- 102000004008 5'-Nucleotidase Human genes 0.000 title claims abstract description 22
- 108010043671 prostatic acid phosphatase Proteins 0.000 title claims abstract description 22
- 238000012360 testing method Methods 0.000 title description 16
- 238000003745 diagnosis Methods 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 48
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000005515 coenzyme Substances 0.000 claims abstract description 35
- 229940107700 pyruvic acid Drugs 0.000 claims abstract description 19
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims abstract description 15
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims abstract description 15
- 108010042687 Pyruvate Oxidase Proteins 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 238000013016 damping Methods 0.000 claims description 25
- 239000012530 fluid Substances 0.000 claims description 25
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 24
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 229910019142 PO4 Inorganic materials 0.000 claims description 21
- 239000010452 phosphate Substances 0.000 claims description 21
- 229930010555 Inosine Natural products 0.000 claims description 17
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 17
- 229960003786 inosine Drugs 0.000 claims description 17
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 14
- 102000016938 Catalase Human genes 0.000 claims description 13
- 108010053835 Catalase Proteins 0.000 claims description 13
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 12
- 238000009007 Diagnostic Kit Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000001186 cumulative effect Effects 0.000 claims description 9
- 230000035484 reaction time Effects 0.000 claims description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 claims description 6
- 235000011089 carbon dioxide Nutrition 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- CXONXVMMINSQBV-NNYOXOHSSA-N (2r,3r,4s,5r)-5-[[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-2-(3-carbamothioylpyridin-1-ium-1-yl)-4-hydroxyoxolan-3-olate Chemical compound NC(=S)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)[O-])=C1 CXONXVMMINSQBV-NNYOXOHSSA-N 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical group NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 229960004418 trolamine Drugs 0.000 claims description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 2
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 claims 1
- PDLNHDSYGLTYDS-UHFFFAOYSA-N 3-aminopropanoic acid;hydrochloride Chemical compound Cl.NCCC(O)=O PDLNHDSYGLTYDS-UHFFFAOYSA-N 0.000 claims 1
- 108010008488 Glycylglycine Proteins 0.000 claims 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- 229940043257 glycylglycine Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 abstract 1
- 102000003992 Peroxidases Human genes 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 235000013902 inosinic acid Nutrition 0.000 abstract 1
- 108040007629 peroxidase activity proteins Proteins 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 4
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010008635 Cholestasis Diseases 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VXEQGQXRKQSAMW-UHFFFAOYSA-N 2-amino-2-methylpropan-1-ol Chemical compound CC(C)(N)CO.CC(C)(N)CO VXEQGQXRKQSAMW-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- PGXABRVTTLRYCN-UHFFFAOYSA-N Cl.Cl.Cl.Cl.C(=O)(O)CCN Chemical compound Cl.Cl.Cl.Cl.C(=O)(O)CCN PGXABRVTTLRYCN-UHFFFAOYSA-N 0.000 description 1
- 208000024815 Granulomatous liver disease Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- ZQYUHRVUJCLGRX-UHFFFAOYSA-N NCC(=O)NCC(O)=O.NCC(=O)NCC(O)=O Chemical compound NCC(=O)NCC(O)=O.NCC(=O)NCC(O)=O ZQYUHRVUJCLGRX-UHFFFAOYSA-N 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 101710171229 Peroxidase 12 Proteins 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000017694 hepatic granuloma Diseases 0.000 description 1
- 231100000843 hepatic granuloma Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- -1 sulfuric acid amine Chemical class 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A reagent kit for diagnosing 5'-nucleotidase is composed of buffer liquid, inosine monophosphate, pyruvic acid, alcohol, oxidized coenzyme, pyruvate oxidase, hydrogen peroxidase, aldehyde dehydrogenase and stabilizer. A process for measuring the activity of 5'-nucleotidase includes such steps as proportionally mixing specimen with reagents, enzyme coupling reaction and biochemically analyzing the final resultant to determine the variation in light absorptivity of master wavelength and in turn the activity of 5'-nucleotidase. Its advantages are high sensitivity and precision, and no pollution.
Description
Technical field
The present invention relates to a kind ofly to measure 5 '-method of activity of 5 '-nucleotidase, the invention still further relates to simultaneously be used to realize 5 of this method '-the phosphonuclease diagnostic kit, belong to medical test determination techniques field.
Background technology
Medical research shows, 5 '-phosphonuclease (5NT) increases and is mainly seen in the obstructive jaundice, also is found in liver cancer and hepatitis.When the concurrent cholangitis of cholestasis, primary and Secondary cases cholehepatocirrhosis and chronic hepatitis, the 5NT rate of rise is higher than alkaline phosphatase; The susceptibility that 5NT raises when liver tumor and hepatic granuloma is higher than alkaline phosphatase.Because 5 '-activity of 5 '-nucleotidase do not have physiological and raise, and is not only responsive than alkaline phosphatase for diagnosis infant's hepatopathy and gestational liver function cholestasis, and specificity is arranged.Therefore measure 5 '-activity of phosphonuclease is significant for the diagnosis of disease.
5 '-activity determination method of phosphonuclease is a lot, mainly contains isotope substrate method, chemical phosphorus acid test method (nineteen twenty-five).Understand according to the applicant, generally adopt the isotropic substance Substrate test method at present in the world, method is: 5 '-phosphonuclease acts on H
3-dUMP, after the termination reaction,, try to achieve 5 by the ion exchange column analytical results '-activity of 5 '-nucleotidase.Perhaps utilize 5 '-phosphonuclease produces inorganic phosphorus after acting on single adenosine phosphate, analyze content of inorganic phosphorus with Chemical acid method again and calculated 5 '-activity of phosphonuclease.
Method of isotope substrate is complicated to also have isotopic contamination, and needs Isotope analyzer, therefore is difficult to apply conscientiously.Determination of inorganic phosphorus is the method for nineteen twenty-five invention, and accuracy is bad, and strong acid contaminate environment or the like also is not suitable for applying.
Summary of the invention
Propose a kind of can overcome 5 of above prior art shortcoming '-measuring method of activity of 5 '-nucleotidase, provide simultaneously in order to realize 5 of this method '-the phosphonuclease diagnostic kit.Adopt reagent in this test kit not only can on ultraviolet analyser or half, automatic clinical chemistry analyzer, carry out 5 '-activity of 5 '-nucleotidase is measured, and finding speed is fast, accuracy is high, thereby can obtain practical applying.
The present invention measures 5 '-step of activity of 5 '-nucleotidase is as follows:
The present invention measures 5 '-step of activity of 5 '-nucleotidase is as follows:
1), with sample and the reagent mix of mainly forming by inosine list phosphoric acid, pyruvic acid, ethanol, oxidized coenzyme, pyruvic oxidase, catalase, aldehyde dehydrogenase, make it to take place the reaction of following method principle:
Inosine list phosphoric acid+water
5 '-phosphonucleaseInosine+phosphate radical
Phosphate radical+pyruvic acid+oxygen+water
Pyruvic oxidaseAcetylphosphate+
Carbonic acid gas+hydrogen peroxide
Hydrogen peroxide+ethanol
CatalaseAcetaldehyde+water
2), detect the end reaction thing in the speed that predominant wavelength 340nm absorbancy descends, calculate 5 '-the active size of phosphonuclease.
Usually step 2) the end reaction thing is placed under ultraviolet analyser or half, the automatic clinical chemistry analyzer device, detect the speed that predominant wavelength 340nm absorbancy descends, calculate 5 '-the active size of phosphonuclease.
The blending ratio of above sample and reagent by volume is 1/10 to 1/250, and the mensuration temperature of above process is controlled at 20 ℃ to 50 ℃ conventional scopes, and the reaction times was controlled at conventional 2-30 minute.
The present invention uses 5 '-enzyme linked reaction system such as phosphonuclease, pyruvic oxidase, catalase, aldehyde dehydrogenase, with inosine list phosphoric acid is substrate, oxidized coenzyme is reduced into reducibility coenzyme the most at last, because reducibility coenzyme has absorption peak at wavelength 340nm, the increase degree of therefore testing wavelength 340nm absorption peak can directly reflect 5 '-size of activity of 5 '-nucleotidase.The advantage of this enzyme linked reaction system has: one, its utilize to measure growing amount that oxidized coenzyme is reduced into reducibility coenzyme and reflect 5 '-activity of 5 '-nucleotidase, the stability of oxidized coenzyme in solution is high more a lot of than reducibility coenzyme, so this system is stable fine.Two, the needs of this enzyme linked reaction system are earlier with the phosphate radical (H that contained originally in body (blood) liquid
2PO
4 -) destroy, otherwise the result understands the not influence of the phosphate radical of equal size in acceptor (blood) liquid.The step of the endogenous phosphate radical of this elimination can be by the allotment double reagent, allows blood sample earlier and in the reagent after second, third and the 4th reaction effect earlier, add again adenosine monophosphate startup 5 '-the phosphonuclease effect.
In order to realize 5 of the inventive method '-the phosphonuclease diagnostic kit can be single agent, comprising:
Damping fluid 40--200mmol/l
Inosine list phosphatase 11--50mmol/l
Pyruvic acid 1--20mmol/l
Ethanol 1--30mmol/l
Oxidized coenzyme 0.5--20mmol/l
Pyruvic oxidase 500--50000U/l
Catalase 500--50000U/l
Aldehyde dehydrogenase 500--50000U/l
Stablizer 10--80% (cumulative volume)
Also above single agent can be made into following pair of agent, more help eliminating inside and outside source phosphate radical and pollute:
Reagent I
Damping fluid 40--200mmol/l
Pyruvic acid 1--20mmol/l
Ethanol 1--30mmol/l
Oxidized coenzyme 0.5--20mmol/l
Pyruvic oxidase 500--50000U/l
Catalase 500--50000U/l
Aldehyde dehydrogenase 500--50000U/l
Stablizer 10--80% (cumulative volume)
Reagent II
Damping fluid 40--200mmol/l
Inosine list phosphatase 11--50mmol/l
Stablizer 10--80mmol/l
Reagent can also be made into following three reagent, not only more help eliminating inside and outside source phosphate radical and pollute, also more help the stable of reagent:
Reagent I
Damping fluid 40--200mmol/l
Pyruvic acid 1--20mmol/l
Ethanol 1--30mmol/l
Oxidized coenzyme 0.5--20mmol/l
Stablizer 10--80mmol/l
Reagent II
Damping fluid 40--200mmol/l
Pyruvic oxidase 500--50000U/l
Catalase 500--50000U/l
Aldehyde dehydrogenase 500--50000U/l
Stablizer 10--80% (cumulative volume)
Reagent III
Damping fluid 40--200mmol/l
Inosine list phosphatase 11--50mmol/l
Stablizer 10--80mmol/l
Three doses prescription is not limited only to above-mentioned prescription, the composition of reagent I wherein, pyruvic acid, ethanol, oxidized coenzyme etc. can be placed among the reagent II, reagent II composition wherein, pyruvic oxidase, catalase, aldehyde dehydrogenase etc. also can be placed among the reagent I, so can form multiple formulations, just not describe in detail one by one at this.
The pH scope of buffer reagent can be 6.0～11.0.Buffer reagent can be three (carboxymethyl) aminomethane-hydrochloric acid (Tris-HCl) damping fluid, trolamine (Triethanolamineo) damping fluid, 2-amino-2-methyl-1-propanol (2-Amino-2-methyl-1-propanol) damping fluid, imidazoles (Imidazole) damping fluid or glycylglycine (Glycylglycine) damping fluid etc., but is not limited only to these damping fluids.
Above oxidized coenzyme can be NADP
+, NAD
+Or thio-NAD
+Deng oxidized form nicotinamide coenzyme or derivatives thereof.
In addition, in order to reduce the cross influence between each reagent composition, the stability of maintenance reagent, so that standing storage, usually add stablizer 10～80% or 10～50mmol/l among reagent I, the reagent II of the reagent I of above single agent, two agent, reagent II or three doses, the reagent III, stablizer can be one or more in ethylene glycol, propylene glycol, glycerine, glycan, polyalcohols, sulfuric acid amine or the salt etc.
Experiment shows, takes all factors into consideration from the accuracy of measurement result and economy two aspects of preparation cost, no matter is single agent, two agent or three doses, the present invention 5 of following system component relation '-the phosphonuclease diagnostic kit is comparatively desirable:
Damping fluid 80--120mmol/l
Adenosine monophosphate 1--5mmol/l
Pyruvic acid 1--10mmol/l
Ethanol 1--10mmol/l
Oxidized coenzyme 1--5mmol/l
Pyruvic oxidase 5000--20000U/l
Catalase 5000--20000U/l
Aldehyde dehydrogenase 5000--20000U/l
Stablizer 10--80% (cumulative volume)
Because the present invention utilizes Enzymology method, enzyme digestion reaction to have the high characteristics of specificity fully, is not vulnerable to the interference of other materials of inside and outside source.Easy, the easy handling of enzyme process method.The specificity of enzyme digestion reaction impels test result accurate.Enzyme digestion reaction all is to carry out under buffer conditions, does not have environmental pollution problem.The enzyme process method does not need special, extra instrument, and testing cost is cheap.Therefore can guarantee to have higher test accuracy, be more convenient for applying.
In addition, one of striking features of the present invention is the pollution that can eliminate inside and outside source phosphate radical, the effect of eliminating inside and outside source phosphate radical occurs in the first half of entire reaction time period, be consumed totally at time second half section contaminated inside and outside source phosphate radical, and second half section time test 5 '-the needed phosphate radical of activity of 5 '-nucleotidase all be result from 5 '-activity of phosphonuclease.
Embodiment
The present invention is further illustrated below in conjunction with examples of implementation.
Embodiment one (single agent)
5 of present embodiment '-the phosphonuclease diagnostic kit comprises:
Damping fluid 80mmol/l
Adenosine monophosphate 1mmol/l
Pyruvic acid 1mmol/l
Ethanol 1mmol/l
Oxidized coenzyme 1mmol/l
Pyruvic oxidase 5000U/l
Catalase 5000U/l
Aldehyde dehydrogenase 5000U/l
Stablizer 50% (cumulative volume)
On automatic clinical chemistry analyzer, set: 37 ℃ of temperature, 10 minutes reaction times, test predominant wavelength 340nm, more than the test commplementary wave length 405nm, tested 5 '-volume ratio of phosphonuclease sample and reagent is 1/25, the Direction of Reaction is positive reaction, 1 minute time of lag, 2 minutes detection times, theoretical k value-4180.
After adding sample and reagent, make it to mix, following reaction take place:
Inosine list phosphoric acid+water
5 '-phosphonucleaseInosine+phosphate radical
Phosphate radical+pyruvic acid+oxygen+water
Pyruvic oxidaseAcetylphosphate+
Carbonic acid gas+hydrogen peroxide
Hydrogen peroxide+ethanol
CatalaseAcetaldehyde+water
Acetaldehyde+oxidized coenzyme+water
Aldehyde dehydrogenaseAcetate+reducibility coenzyme+hydrogen ion
The end reaction thing is placed under the biochemical analyzer, detect the speed that predominant wavelength 340nm absorbancy rises, thereby calculate 5 '-the active size of phosphonuclease.
Present embodiment uses 5 '-enzyme linked reaction systems such as phosphonuclease, pyruvic oxidase, catalase, aldehyde dehydrogenase, with inosine list phosphoric acid is substrate, oxidized coenzyme is reduced into reducibility coenzyme the most at last, because reducibility coenzyme has absorption peak at wavelength 340nm, the increase degree of therefore testing wavelength 340nm absorption peak can directly reflect 5 '-size of activity of 5 '-nucleotidase.
Embodiment two (two agent)
5 of present embodiment '-the phosphonuclease diagnostic reagent has:
Reagent I
Damping fluid 100mmol/l
Pyruvic acid 6mmol/l
Ethanol 6mmol/l
Oxidized coenzyme 6mmol/l
Pyruvic oxidase 12000U/l
Hydrogen peroxidase 12 000U/l
Aldehyde dehydrogenase 12000U/l
Stablizer 50% (cumulative volume)
Reagent II
Damping fluid 100mmol/l
Inosine list phosphoric acid 3mmol/l
Stablizer 30mmol/l
Measure 5 '-during activity of 5 '-nucleotidase, temperature is controlled at 30 ℃, 15 minutes reaction times, test predominant wavelength 340nm, more than the test commplementary wave length 405nm, tested 5 '-volume ratio of phosphonuclease sample and reagent is 1/25, the Direction of Reaction is positive reaction, 1 minute time of lag, 2 minutes detection times, theoretical k value-4180.
Concrete determination step is:
Inosine list phosphoric acid+water
5 '-phosphonucleaseInosine+phosphate radical
Phosphate radical+pyruvic acid+oxygen+water
Pyruvic oxidaseAcetylphosphate+
Carbonic acid gas+hydrogen peroxide
Hydrogen peroxide+ethanol
CatalaseAcetaldehyde+water
Acetaldehyde+oxidized coenzyme+water
Aldehyde dehydrogenaseAcetate+reducibility coenzyme+hydrogen ion
The end reaction thing is placed under the biochemical analyzer, detect the speed that predominant wavelength 340nm absorbancy rises, thereby calculate 5 '-the active size of phosphonuclease.
The reaction times of each reactions steps was controlled at 15 minutes.
Embodiment three (three doses)
5 of present embodiment '-the phosphonuclease diagnostic reagent is three doses, has:
Reagent I
Damping fluid 120mmol/l
Pyruvic acid 10mmol/l
Ethanol 10mmol/l
Oxidized coenzyme 5mmol/l
Stablizer 50mmol/l
Reagent II
Damping fluid 120mmol/l
Pyruvic oxidase 20000U/l
Catalase 20000U/l
Aldehyde dehydrogenase 20000U/l
Stablizer 50% (cumulative volume)
Reagent III
Damping fluid 120mmol/l
Inosine list phosphoric acid 5mmol/l
Stablizer 50mmol/l
On automatic clinical chemistry analyzer, set: 25 ℃ of temperature, 20 minutes reaction times, test predominant wavelength 340nm, more than the test commplementary wave length 405nm, tested 5 '-volume ratio of phosphonuclease sample and reagent is 1/25, the Direction of Reaction is positive reaction, 1 minute time of lag, 2 minutes detection times, theoretical k value-4180.
Concrete determination step is:
Inosine list phosphoric acid+water
5 '-phosphonucleaseInosine+phosphate radical
Phosphate radical+pyruvic acid+oxygen+water
Pyruvic oxidaseAcetylphosphate+
Carbonic acid gas+hydrogen peroxide
Hydrogen peroxide+ethanol
CatalaseAcetaldehyde+water
Acetaldehyde+oxidized coenzyme+water
Aldehyde dehydrogenaseAcetate+reducibility coenzyme+hydrogen ion
The end reaction thing is placed under the biochemical analyzer, detect the speed that predominant wavelength 340nm absorbancy rises, thereby calculate 5 '-the active size of phosphonuclease.
The reaction times of each reactions steps was controlled at 20 minutes.
Embodiment four
5 of present embodiment '-the phosphonuclease diagnostic reagent has:
Reagent I
Damping fluid 100mmol/l
Pyruvic acid 5mmol/l
Ethanol 2mmol/l
Oxidized coenzyme 1mmol/l
Pyruvic oxidase 10000U/l
Catalase 8000U/l
Aldehyde dehydrogenase 6000U/l
Stablizer 50% (cumulative volume)
Reagent II
Damping fluid 100mmol/l
Inosine list phosphatase 11 mmol/l
Stablizer 20mmol/l
On Biochemical Analyzer, set: 37 ℃ of temperature, 10 minutes reaction times, test predominant wavelength 340nm, more than the test commplementary wave length 405nm, tested 5 '-volume ratio of phosphonuclease sample and reagent is 1/25, the Direction of Reaction is positive reaction, 1 minute time of lag, 2 minutes detection times, theoretical k value-4180.
After adding sample and reagent, make it to mix, following reaction take place:
Inosine list phosphoric acid+water
5 '-phosphonucleaseInosine+phosphate radical
Phosphate radical+pyruvic acid+oxygen+water
Pyruvic oxidaseAcetylphosphate+
Carbonic acid gas+hydrogen peroxide
Hydrogen peroxide+ethanol
CatalaseAcetaldehyde+water
Acetaldehyde+oxidized coenzyme+water
Aldehyde dehydrogenaseAcetate+reducibility coenzyme+hydrogen ion
The end reaction thing is placed under the biochemical analyzer, detect the speed that predominant wavelength 340nm absorbancy rises, thereby calculate 5 '-the active size of phosphonuclease.
In a word, experiment showed, and adopt measuring method of the present invention can draw required measurement result by ultraviolet analyser or half, automatic clinical chemistry analyzer device fully, and highly sensitive, tolerance range good, is not subjected to the pollution of inside and outside source material.
Claims (9)
1. one kind 5 '-the activity of 5 '-nucleotidase measuring method, step is as follows:
1), with sample and the reagent mix of mainly forming by inosine list phosphoric acid, pyruvic acid, ethanol, oxidized coenzyme, pyruvic oxidase, catalase, aldehyde dehydrogenase, make it to take place following reaction:
Inosine list phosphoric acid+water
5 '-phosphonucleaseInosine+phosphate radical
Phosphate radical+pyruvic acid+oxygen+water
Pyruvic oxidaseAcetylphosphate+
Carbonic acid gas+hydrogen peroxide
Hydrogen peroxide+ethanol
CatalaseAcetaldehyde+water
2), detect the end reaction thing in the speed that predominant wavelength 340nm absorbancy descends, calculate 5 '-the active size of phosphonuclease.
According to claim 1 described 5 '-the activity of 5 '-nucleotidase measuring method, it is characterized in that: described step 2) be, the end reaction thing is placed under ultraviolet analyser or half, the automatic clinical chemistry analyzer, detect predominant wavelength 340nm, the speed that absorbancy descends, calculate 5 '-the active size of phosphonuclease.
3, according to claim 1 or 2 described mensuration 5 '-method of activity of 5 '-nucleotidase, it is characterized in that: temperature is controlled at 20 ℃ to 50 ℃ scopes, and the reaction times was controlled at 2-30 minute.
4, according to claim 1 or 2 described mensuration 5 '-method of activity of 5 '-nucleotidase, it is characterized in that: tested 5 '-ratio control of phosphonuclease sample and reagent is 1/10 to 1/500.
5. one kind 5 '-the phosphonuclease diagnostic kit, be grouped into by following one-tenth:
Damping fluid 40--200mmol/l
Inosine list phosphatase 11--50mmol/l
Pyruvic acid 1--20mmol/l
Ethanol 1--30mmol/l
Oxidized coenzyme 0.5--20mmol/l
Pyruvic oxidase 500--50000U/l
Catalase 500--50000U/l
Aldehyde dehydrogenase 500--50000U/l
Stablizer 10--80% (cumulative volume)
According to claim 5 described 5 '-the phosphonuclease diagnostic kit, it is characterized in that: described reagent is made into single agent, two agent or three doses.
According to claim 5 or 6 described 5 '-the phosphonuclease diagnostic kit, it is characterized in that: described stablizer is at least a in ethylene glycol, propylene glycol, glycerine, glycan, polyalcohols, ammonium sulfate or the salt.
According to claim 5 or 6 described 5 '-the phosphonuclease diagnostic kit, it is characterized in that: described buffer reagent is a kind of in three (carboxymethyl) aminomethane-hydrochloride buffer, trolamine damping fluid, 2-amino-2-methyl-1-propanol damping fluid or the glycylglycine damping fluid.
9, according to claim 5 or 6 described 5 '-the phosphonuclease diagnostic kit, it is characterized in that: described oxidized coenzyme is NADP
+, NAD
+Or thio-NAD
+A kind of in the oxidized form nicotinamide coenzyme or derivatives thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410064908 CN1760370A (en) | 2004-10-11 | 2004-10-11 | Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410064908 CN1760370A (en) | 2004-10-11 | 2004-10-11 | Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1760370A true CN1760370A (en) | 2006-04-19 |
Family
ID=36706591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410064908 Pending CN1760370A (en) | 2004-10-11 | 2004-10-11 | Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1760370A (en) |
-
2004
- 2004-10-11 CN CN 200410064908 patent/CN1760370A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1769481A (en) | Blood ammonia content determination method and blood ammonia diagnosis kit | |
| CN1749756A (en) | Method for detecting blood ammonia content and blood ammonia diagnostic reagent kit | |
| CN1778963A (en) | Determination of blood ammonia content and blood ammonia diagnostic reagent kit | |
| CN1760370A (en) | Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase | |
| CN1760372A (en) | Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase | |
| CN1749407A (en) | Method for measuring 5'-nucleotidase activity and diagnostic reagent kit of 5'-nucleotidase | |
| CN1749411A (en) | Method for measuring 5'-nucleotidase activity and diagnostic kit of 5'-nucleotidase | |
| CN1778947A (en) | Creatinine content determination and creatinine diagnostic reagent kit | |
| CN1746316A (en) | Determination of adenosine deaminase activity and diagnostic kit of adenosine deaminase | |
| CN1749405A (en) | Method for measuring 5'-nucleotidase activity and Diagnostic reagent kit of 5'-nucleotidase | |
| CN1766640A (en) | Creatinine content determination method and creatinine diagnosis kit | |
| CN1778964A (en) | Determination of 5'-nucleotidase activity and its diagnostic reagent kit of 5'-nucleotidase | |
| CN1760373A (en) | Method for testing activity of 5'-nucleotidase, and diagnosis kit for 5'-nucleotidase | |
| CN1760371A (en) | Method for testing activity of 5'-nucleotidase, and diagnosis kit for 5'-nucleotidase | |
| CN1749408A (en) | Method for measuring 5'-nucleotidase activity and diagnostic reagent kit of 5'-nucleotidase | |
| CN1760374A (en) | Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase | |
| CN1778965A (en) | Determination of 5'-nucleotidase acitivity and its diagnostic reagent kit of 5'-nucleotidase | |
| CN1757754A (en) | Determination method of creatnine content and reagent box for diagnosing creatnine | |
| CN1757748A (en) | Determination method of creatnine content and creatnine diagnosis reagent box | |
| CN1766638A (en) | Creatinine content determination method and creatinine diagnosis kit | |
| CN1757751A (en) | Determination method of creatnine content and reagent box for diagnosing creatnine | |
| CN1749406A (en) | Method for measuring 5'-nucleotidase activity and diagnostic reagent kit of 5'-nucleotidase | |
| CN1760367A (en) | Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase | |
| CN1778946A (en) | Determination of blood ammonia content and blood ammonia diagnostic reagent kit | |
| CN1760368A (en) | Method for testing activity of 5'-nucleotidase, diagnosis kit for 5'-nucleotidase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |